



Original article

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

The COVID-19 RISK and Treatments (CORIST) Collaboration^{1,*}

ARTICLE INFO

Keywords:

Hydroxychloroquine
 COVID-19
 Disease severity
 Mortality
 Inflammation

ABSTRACT

Background: Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19.

Objective: We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality.

Methods: In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses.

Results: Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% lower risk of death in patients receiving HCQ (HR=0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry.

Conclusions: HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.

1 1. Introduction

2 The aminoquinoline hydroxychloroquine (HCQ) has been extensively used in the treatment of malaria and is currently widely used to treat autoimmune diseases like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), due to its immunomodulatory and anti-thrombotic properties [1]. More recently, a promising role of HCQ has been suggested in viral infections [2], since it directly inhibits viral entry and spread in several *in vitro* and *in vivo* models. Due to these properties, HCQ has been used in Ebola virus disease [3,4], human immunodeficiency virus (HIV) infection [5], SARS-CoV-1 infection and the Middle East Respiratory Syndrome (MERS) [6,7] and gained worldwide attention as a possible therapy in COVID-19 patients [8].

14 HCQ might inhibit the intracellular glycosylation of ACE 2, the receptor used by the SARS-CoV-2 virus to enter the cells, resulting in a

reduced ligand recognition and internalization of the virus [7] and exerting a possible protective role in SARS-CoV-2 infection. Moreover, due to its immunomodulatory, anti-inflammatory and anti-thrombotic effects, HCQ could also modulate the severity of the disease. However, the exact mechanism for the potential benefit in COVID-19 is largely speculative [9] and might be counterbalanced by adverse effects, mainly cardiovascular [10,11], so that the net balance of this drug's use remains to be established.

The American Food and Drug Administration (FDA) allowed Chloroquine (CQ) phosphate and HCQ to be provided to certain hospitalized patients because these drugs may possibly help patients with severe COVID-19 [12]. The European Medicines Agency (EMA) authorized the use of CQ and HCQ for COVID-19 in clinical trials or as emergency use [13], while the Italian Drug Agency (AIFA) stated in this emergency phase that therapeutic use of HCQ might be considered in COVID-19 patients, both in those with mild presentation managed at home and in

* Corresponding author at: Department of Epidemiology and Prevention, IRCCS Neuromed, Via dell'Elettronica, 86077 Pozzilli (IS), Italy.

E-mail address: licia.iacoviello@moli-sani.org

¹ The members of The COVID-19 RISK and Treatments (CORIST) Collaboration are listed in Appendix 1 at the end of the article.

hospitalized patients [14]. In clinical practice, HCQ rather than chloroquine has been used because of its more potent antiviral properties and better safety profile [15].

However, in the light of a recent publication [16], that was later retracted [17], on the lack of safety and efficacy of HCQ in the treatment for COVID-19 patients the Executive Group of the Solidarity Trial decided to implement a temporary pause of the HCQ arm within the trial as a precaution, while the safety data is being reviewed [18]. Similarly, the Italian drug Agency AIFA decided to suspend the authorization to use HCQ for COVID-19 treatment outside clinical trials [19].

Recent reviews of clinical trials or observational studies [20–24] have reported insufficient and often conflicting evidence on the benefits and harms of using HCQ to treat COVID-19 and concluded that as such, it was impossible to determine the balance of benefits to harm. Until now, although several trials had been started on the use of CQ and HCQ in COVID-19, only few of them have been published [25] on small numbers of patients or on surrogate endpoints or in exposed subjects for prophylaxis use [26].

While waiting the results from ongoing randomized clinical trials (RCT) to define the efficacy in preventing hard endpoints of this treatment so widely used during the emergency phase of the COVID-19 pandemic, powered retrospective observational studies performed in different geographical and disease conditions may still be useful to shed light on this debate. Two retrospective observational studies, both conducted in the New York metropolitan region, did not report any significant association between HCQ use and rates of intubation or death [27,28].

No data are presently available from large cohorts of patients in Italy, which represents one of the most affected countries in terms of total deaths for COVID-19 in the world [29]. We undertook a multicenter Italian collaboration [30] to investigate the relationship between underlying risk factors and COVID-19 outcomes, and to evaluate the association between different drug therapy and disease severity and/or mortality. We report here the results obtained in 3,451 hospitalized COVID-19 patients receiving or not HCQ treatment.

2. Material and methods

2.1. Setting

This national retrospective observational study was conceived, coordinated and analysed within the CORIST Project (ClinicalTrials.gov ID: NCT04318418, 30). The study was approved by the institutional ethics board of the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Pozzilli, and of all recruiting centres. Data for the present analyses were provided by 33 hospitals distributed throughout Italy (listed in the supplementary file). Acceptance to participate in the project or to provide data for the present analysis was not related to the use of CQ/HCQ. Each hospital provided data from hospitalized patients who had a positive test result for the SARS-CoV-2 virus at any time during their hospitalization from February 19 to May 23, 2020. The follow-up continued through May 29, 2020.

2.2. Data sources

We developed a cohort comprising 3,971 patients with laboratory-confirmed SARS-CoV-2 infection in an in-patient setting. The SARS-CoV-2 status was declared based on laboratory results (polymerase chain reaction on nasopharyngeal swab) from each participating hospital. Clinical data were abstracted at one-time point from electronic medical records or charts, and were collected using either a centrally designed electronic worksheet or a centralized web-based database. Collected data included patients' demographics, laboratory test results, medication administration, historical and current medication lists, historical and current diagnoses, and clinical notes. In addition, specific information on the most severe manifestation of COVID-19 occurred during

hospitalization was retrospectively captured. Maximum clinical severity observed was classified as mild pneumonia; or severe pneumonia; or acute respiratory distress syndrome (ARDS) [31]. Specifically, we obtained the following information for each patient: hospital; date of admission and date of discharge or death; age; sex; the first recorded inpatient laboratory tests at the entry (creatinine, C-reactive protein); past and current diagnoses (myocardial infarction, heart failure, diabetes, hypertension, respiratory disease and cancer) and current drug therapies for COVID-19 – HCQ, lopinavir/ritonavir or darunavir/cobicistat, remdesivir, tocilizumab or sarilumab, corticosteroids, heparin, and for comorbidities (insulin, anti-hypertensive treatments, aldosterone receptor antagonists, diuretics, statins, sacubitril/valsartan). A diagnosis of pre-existing cardiovascular disease was based on history of myocardial infarction or heart failure. Chronic kidney disease was classified as: stage 1: kidney damage with normal or increased glomerular filtration rate (GFR) (>90 mL/min/1.73 m²); stage 2: mild reduction in GFR (60–89 mL/min/1.73 m²); stage 3a: moderate reduction in GFR (45–59 mL/min/1.73 m²); stage 3b: moderate reduction in GFR (30–44 mL/min/1.73 m²); stage 4: severe reduction in GFR (15–29 mL/min/1.73 m²); stage 5: kidney failure (GFR <15 mL/min/1.73 m² or dialysis). For statistical analysis, stages 3a and 3b and stages 4 and 5 were combined. GFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation. Patients were defined as receiving HCQ if they were receiving it at admission to hospital or received it during the follow-up period. According to the AIFA guidance [14], HCQ was administered at dose of 400 mg x 2/day or x4/day the first day, and 200 mg x 2/day from the second day onwards for at least 5 to a maximum of 10 days, according to the clinical evolution of the disease.

2.3. Statistical analysis

The study index date was defined as the date of hospital admission. Index dates ranged from February 19, 2020 to May 23, 2020. The study end point was the time from study index to death. The number of patients who either died, or had been discharged alive, or were still admitted to hospital as of May 29, 2020, were recorded, and hospital length of stay was determined. Patients alive had their data censored on the date of discharge or as the date of the respective clinical data collection. Data were censored at 35 days of follow up in $n=330$ (8.3%) patients with a follow up greater than 35 days.

Of the initial cohort of 3,971 patients, 350 patients were excluded from the analysis because they had at least one missing data at baseline or lost to follow up on HCQ use ($N=94$), other drug therapies for COVID-19 ($n=265$), time to event ($n=59$), outcome (death/alive, $n=8$), COVID-19 severity ($n=4$), age ($n=4$ with missing data and $n=2$ with age <18 years) or sex ($n=2$). Of the remaining 3,621 patients, 170 patients died or were discharged within 24 hours after presentation, and were also excluded from the analysis.

At the end, the analysed cohort consisted of $n=3,451$ patients. In patients not included in the analysis ($n=520$), as unique difference with the analysed group, the prevalence of diabetics (19.9% vs 14.8%, $P=0.0066$) and, to a less extent, of men (62.3% vs 58.3%, $P=0.081$) was higher. Out of 3,541 patients, 295 (8.5%) had at least a missing value for covariates. Distribution of missing values was as follows: $n=178$ for C-reactive protein; $n=69$ for GFR; $n=74$ for history of ischemic disease; $n=64$ for history of chronic pulmonary disease; $n=51$ for diabetes; $n=51$ for hypertension and $n=56$ for cancer. We used multiple imputation techniques (SAS PROC MI, $n=10$ imputed datasets; and PROC MIANALYZE) to maximize data availability. As sensitivity analysis, we also conducted a case-complete analysis on 3,156 patients.

Cox proportional-hazards regression models were used to estimate the association between HCQ use and death. Since multiple imputation was applied, the final standard error was obtained using the Rubin's rule based on the robust variance estimator in Cox regression [32]. The proportional hazards assumption was assessed using weighed Schoen-

feld residuals, and no violation was identified. To account for the non-randomized HCQ administration and to reduce the effects of confounding, the propensity-score method was used. The individual propensities for receiving HCQ treatment were assessed with the use of a multivariable logistic-regression model that included age, sex, diabetes, hypertension, history of ischemic heart disease, chronic pulmonary disease, GFR, C-reactive protein, hospitals clustering and use of other drug therapies for COVID-19 (lopinavir/ritonavir or darunavir/cobicistat, remdesivir, corticosteroids, tocilizumab or sarilumab). Associations between HCQ treatment and death was then appraised by multivariable Cox regression models with the use of propensity-score and further controlling for hospitals clustering as random effect (frailty model). The use of a frailty model was chosen as suggested in [33]. The primary analysis used inverse probability by treatment weighting; the predicted probabilities from the propensity-score model was used to calculate the stabilized inverse-probability-weighting weight [34]. Stabilized weights were normalized so that they added up the actual sample size. Secondary analyses used propensity-score stratification (n=5 strata) or multivariable Cox regression analysis or multivariable logistic regression analyses comparing death versus alive patients, or accounted for hospitals clustering via stratification or by robust sandwich estimator. Pre-established subgroup analyses were conducted according to age or sex of patients, degree of COVID-19 severity experienced during the hospital stay, C-reactive protein at basal or other drug therapies for COVID-19. Hospitals were clustered according to their geographical distribution, as illustrated in Table 1. To quantify the potential for an unmeasured confounder to render apparent statistically significant hazard ratio non-significant, the E-value was calculated [35]. Analyses were performed with the aid of the SAS version 9.4 statistical software for Windows.

3. Results

We included in the final current analyses 3,451 patients who were hospitalized with confirmed SARS-CoV-2 infection at 33 clinical centres across Italy and either died, had been discharged, or were still in hospital as of May 29, 2020. Of these patients, 2,634 (76.3%, range among hospitals 53.2% to 93.6%) received HCQ. Timing of the first dose of HCQ after presentation to the hospital was 1 day for the large majority of centres, and 2 to 3 days for the others. HCQ was administered in all centres at the dose of 400 mg/day (in one centre however it was used at the dose of 600 mg/day and in another at the dose of 600 mg/day but only in patients younger than 65 years). Duration of treatment ranged from 5 to 15 days (with 10 days as the modal value). The drug used was HCQ in all hospitals.

Baseline characteristics according to HCQ use are shown in Table 1. Patients receiving HCQ were more likely younger, men and had higher levels of C-reactive protein and less likely had ischemic heart disease, cancer or stages 3a or greater chronic kidney disease (Table 1). Patients receiving HCQ more likely received another drug for COVID-19 treatment (78.4%; lopinavir/ritonavir or darunavir/cobicistat, remdesivir, tocilizumab or sarilumab, corticosteroids), in comparison with non-HCQ patients (46.3%; $P < 0.0001$; Table 1).

The unadjusted differences and differences adjusted by propensity scores between HCQ-treated and non-HCQ treated patients for each variable included in the propensity score are shown in Fig. 1. All the pre-treatment differences disappeared after adjustment by propensity score weighting. The C-statistic of the propensity-score model was 0.74.

3.1. Primary outcome

Out of 3,628 patients, 576 died (16.7%), 2,390 were discharged alive (69.3%) and 485 (14.1%) were still at the hospital. The median follow-up was 14 days (interquartile range 8 to 22; range 2 to 35; 55,388 person-days). Death rate (per 1,000 person-days) was 8.9 in HCQ and

15.7 in non-HCQ patients (Table 2). At univariable analysis, hazard ratio for mortality was 0.56 (95%CI: 0.47 to 0.67). In the primary multivariable analysis with inverse probability weighting according to the propensity score, HCQ use was associated with a 30% (95%CI: 16% to 41%) reduction in death risk (Fig. 2, Table 2, E-value=1.67). Secondary multivariable analyses yielded very similar results (Table 2), as well as case-complete analyses restricted to the 3,156 patients without missing data (Table 2). Considering secondary multivariable analyses overall, HR for mortality associated with HCQ ranged between 0.64 to 0.70, according to type of analyses. Control of hospitals clustering with different approaches also yielded similar results for the primary analysis (HR=0.71, 95%CI: 0.59 to 0.85 when hospitals clustering was stratified for and HR=0.69, 95%CI: 0.54 to 0.88 with the robust sandwich estimator).

Subgroup analyses are presented in Table 3. HCQ use remained consistently associated with reduced mortality in almost all subgroups. The inverse association of HCQ with inpatient mortality is slightly more evident in women, elderly and in patients who experienced a higher degree of COVID-19 severity. It was absent in-patient with C-reactive protein < 10 mg/L and clearly confined to patients with elevated C-reactive protein (Table 3).

4. Discussion

In a large cohort of 3,451 patients hospitalized for COVID-19 in 33 clinical centers all over Italy, covering almost completely the period of the hospitalization for COVID-19, the use of HCQ was associated with a significant better survival. In-hospital crude death rate was 8.9 per 1,000 person-day for patients receiving HCQ and 15.7 for those who did not. After adjustment for known possible confounders, we observed a 30% reduction in the risk of death in patients receiving HCQ therapy as compared with those who did not.

Our findings provide clinical evidence in support of guidelines by Italian and several international Societies suggesting to use HCQ therapy in patients with COVID-19. However, the observed associations should be considered with caution, as the observational design of our study does not allow to fully excluding the possibility of residual confounders. Large randomized clinical trials in well-defined geographical and socio-economic conditions and in well-characterized COVID-19 patients, should evaluate the role of HCQ before any firm conclusion can be reached regarding a potential benefit of this drug in patients with COVID-19.

Over 76% of patients received HCQ either alone or in combination with other drugs. They were more likely to be younger, men and with higher levels of C reactive protein at entry, while less likely had pre-existing comorbidities such as ischemic heart disease, cancer and severe chronic kidney disease, as compared to patients not receiving the drug. We adjusted our analyses for possible confounders, including age, sex, diabetes, hypertension, history of ischemic heart disease, chronic pulmonary disease, chronic kidney disease, C-reactive protein and additional treatments for COVID-19, and took into account possible differences across centres by either adjustment or stratification. To minimize bias due to the observational design, we used different analytical approaches aiming at creating an overall balance between comparison groups. Finally, we tried to limit bias due to missing data by using a multiple imputation approach, but in no case, the result was changed. Despite all these precautions, we recognize the possibility, however, of residual unmeasured confounders affecting results.

Systematic reviews of small clinical trials had reported contrasting results that were however scarcely reliable because of poor designs [20–25]. The HCQ doses tested in a Chinese randomized clinical trial [25] were approximately double as compared to that used in our study (1200 mg vs 800 mg as loading dose, 800 mg vs 400 mg as maintenance dose) for twice the time (14–21 days versus 7–10 days). National guidelines in Italy suggest to use HCQ 200 mg

Table 1
General characteristics of COVID-19 patients at baseline, according to hydroxychloroquine use.

Characteristic	Hydroxychloroquine		P-value unadjusted*
	No (N=817)	Yes (N=2,634)	
Age-median (IQR-yr.)	73 (58-83)	66 (55-77)	<.0001
Gender- no (%)			<.0001
Women	361 (44.2%)	940 (36.7%)	
Men	456 (55.8%)	1,694 (64.3%)	
Diabetes- no (%)			0.71
No	633 (77.5%)	2,090 (79.3%)	
Yes	162 (19.9%)	515 (19.6%)	
missing data	22 (2.7%)	29 (1.1%)	
Hypertension - no (%)			0.31
No	378 (46.3%)	1,294 (49.1%)	
Yes	416 (50.9%)	1,312 (49.8%)	
missing data	23 (2.7%)	28 (1.1%)	
Ischemic heart disease- no (%)			<.0001
No	610 (74.7%)	2,190 (83.1%)	
Yes	179 (21.9%)	398 (15.1%)	
missing data	28 (3.4%)	46 (1.8%)	
Chronic pulmonary disease- no (%)			0.21
No	666 (81.5%)	2,225 (84.5%)	
Yes	127 (15.5%)	369 (14.0%)	
missing data	24 (2.9%)	40 (1.5%)	
Cancer- no (%)			0.036
No	694 (84.9%)	2,338 (88.8%)	
Yes	101 (12.4%)	262 (9.9%)	
missing data	22 (2.6%)	34 (1.3%)	
CKD stage**- no (%)			<.0001
Stage 1	241 (29.5%)	970 (36.8%)	
Stage 2	281 (34.4%)	991 (37.6%)	
Stage 3a or stage 3b	180 (22.0%)	487 (18.5%)	
Stage 4 or stage 5	89 (10.9%)	143 (5.4%)	
missing data	26 (3.2%)	43 (1.6%)	
C Reactive Protein- no (%)			0.0003
<1 mg/L	104 (12.7%)	256 (9.7%)	
1-3 mg/L	120 (14.7%)	301 (11.4%)	
>3 mg/L	549 (67.2%)	1,943 (73.8%)	
missing data	44 (5.4%)	134 (5.1%)	
Lopinavir or Darunavir use			<.0001
No	621 (76.0%)	1,203 (36.7%)	
Yes	196 (24.0%)	1,431 (64.3%)	
Tocilizumab or Sarilumab use			<.0001
No	755 (92.4%)	2,160 (82.0%)	
Yes	62 (7.6%)	474 (18.0%)	
Remdesivir use			0.0015
No	808 (98.9%)	2,551 (96.9%)	
Yes	9 (1.1%)	83 (3.1%)	
Corticosteroids use			<.0001
No	596 (73.0%)	1,655 (62.8%)	
Yes	221 (27.0%)	979 (37.2%)	
Clusters of hospitals			<.0001
Northern regions (except Milan) (n)	169 (20.7%)	616 (23.4%)	
Milan (m)	161 (19.7%)	525 (19.9%)	
Center regions (except Rome) (c)	303 (37.1%)	747 (28.4%)	
Rome (r)	94 (11.5%)	390 (14.8%)	
Southern regions (s)	90 (11.0%)	356 (13.5%)	

(n) include hospitals of Novara, Monza, Varese, Pavia, Cremona and Padova; (m) include Humanitas Clinical and Research Hospital, Centro Cardiologico Monzino, and hospitals of San Donato Milanese (Milano) and Cinisello Balsamo (Milano); (c) include hospitals of Modena, Ravenna, Forlì, Firenze, Pisa, Chieti and Pescara; (r) include National Institute for Infectious Diseases "L. Spallanzani" and Università Cattolica del Sacro Cuore; (s) include hospital of Napoli, Pozzilli (Isernia), Acquaviva delle Fonti (Bari), Foggia, Taranto, Catanzaro, Catania and Palermo *Chi-square test. **Stage 1: Kidney damage with normal or increased glomerular filtration rate (GFR) (>90 mL/min/1.73 m²); Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m²); Stage 3a: Moderate reduction in GFR (45-59 mL/min/1.73 m²); Stage 3b: Moderate reduction in GFR (30-44 mL/min/1.73 m²); Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m²); Stage 5: Kidney failure (GFR < 15 mL/min/1.73 m² or dialysis).

281 twice daily for at least 5-7 days in patients over 70 years and/or
 282 with co-morbidities (chronic obstructive pulmonary disease, diabetes,
 283 cardiovascular disease) even with mild respiratory symptoms or with
 284 radiographically documented pneumonia or in severe patients [36].
 285 The lower doses of HCQ used in our centers, as suggested by Italian

official guidelines [19,36], may have been both more effective and
 safer.

Two recently published large observational studies, both from large
 hospitals in New York City, showed no association between HCQ use
 and in-hospital mortality [27,28], and deserve specific discussion. In the

Table 2
Incidence rates and hazard ratios for death in COVID-19 patients, according to hydroxychloroquine use.

Multiple imputation analysis (N=3,451)				
	Death (N=576)	Patient at risk (N=3,451)	Person-days	Death Rate (x1,000 person-days)
Hydroxychloroquine				
No- no. (%)	190 (23.3%)	817 (100%)	12,084	15.7
Yes- no. (%)	386 (14.7%)	2,634 (100%)	43,304	8.9
Hazard ratio for death (HCQ versus non HCQ)				
Crude analysis				0.56 (0.47 to 0.67)
Multivariable analysis*				0.70 (0.58 to 0.85)
Propensity score analysis, inverse probability weighting** (primary analysis)				0.70 (0.59 to 0.84)
Propensity score analysis, stratification (n=5 strata)**				0.67 (0.56 to 0.81)
Odds ratio for death (HCQ versus non HCQ)				
Propensity score analysis, inverse probability weighting**				0.67 (0.54 to 0.82)
Case Complete Analysis (N=3,156)				
	Death (N=510)	Patient at risk (N= 3,156)	Person-days	Death Rate (x1,000 person-days)
Hydroxychloroquine				
No- no. (%)	170 (22.9%)	741 (100%)	11,050	15.4
Yes- no. (%)	340 (14.1%)	2,415 (100%)	39,274	8.7
Hazard ratio for death (HCQ versus non HCQ)				
Crude analysis				0.56 (0.46 to 0.67)
Multivariable analysis*				0.71 (0.59 to 0.86)
Propensity score analysis, inverse probability weighting**				0.64 (0.53 to 0.76)
Propensity score analysis, stratification (n=5 strata)**				0.68 (0.56 to 0.82)
Odds ratio for death (HCQ versus non HCQ)				
Propensity score analysis, inverse probability weighting**				0.67 (0.54 to 0.82)

Abbreviations: HR, hazard ratios; CI, confidence intervals. *Controlling for age, sex, diabetes, hypertension, history of ischemic heart disease, chronic pulmonary disease, chronic kidney disease, C-reactive protein, lopinavir/ritonavir or darunavir/cobicistat, tocilizumab or sarilumab, remdesivir or corticosteroids use as fixed effects and hospitals clustering as random effect. **Including hospitals clustering as random effect covariate.

291 study of Geleris et al. [27], the percentage use of HCQ was lower than in
 292 Italy; moreover, in both US studies [27,28] the drug was more frequently
 293 administered to patients with previous illnesses and a more severe pre-
 294 sentation of the disease. Our cohort included milder pneumonia patients
 295 than the US population, due to between-country differences in indica-

296 tions to the drug for the beginning of therapy (e.g., mild pneumonia in
 297 Italy versus only severe pneumonia and ARDS in the US). Concomitant
 298 use of other drugs for COVID-19 was very low in one study [27] and was
 299 not reported in the other study [28]. In our cohort, patients receiving
 300 HCQ were more likely treated with another drug for COVID-19 treat-




Fig. 1. The unadjusted standardized differences and standardized differences adjusted by propensity scores between HCQ-treated and non-HCQ treated patients for the variables included in the propensity score. All differences for the matched observations are within the recommended limits of -0.25 and 0.25, which are indicated by reference lines.




Fig. 2. Survival curves according to hydroxychloroquine use. The curves are adjusted by propensity score analysis (inverse probability for treatment weighting) and hospital index as random effect, and are generated using the first imputed dataset. The other imputed datasets are similar and thus omitted.

Table 3

Hazard ratios for mortality according to hydroxychloroquine use in different subgroups.

	Hydroxychloroquine NO (N=817)	Hydroxychloroquine YES (N=2,634)	
Subgroups	No. death/patient at risk	No. death/patient at risk	HR (95% CI)*
Women	80/361	116/940	0.63 (0.46 to 0.86)
Men	110/456	270/1,694	0.74 (0.60 to 0.93)
Age <70 years	22/357	93/1,542	0.76 (0.50 to 1.16)
Age ≥70 years	168/460	293/1,092	0.68 (0.56 to 0.83)
Highest degree of COVID-19 severity experienced at hospital			
Mild pneumonia or less	28/424	40/1,358	0.70 (0.41 to 1.18)
Severe pneumonia	80/253	172/764	0.76 (0.58 to 0.99)
Acute respiratory distress syndrome	82/140	174/512	0.68 (0.52 to 0.90)
Use of other COVID-19 treatments[^]			
No	101/439	64/570	0.63 (0.45 to 0.88)
Yes	89/378	322/2,064	0.77 (0.61 to 0.99)
C-Reactive Protein at basal^{**}			
<10 mg/L	56/412	125/1,138	1.23 (0.86 to 1.77)
≥10 mg/L	123/361	241/1,362	0.59 (0.47 to 0.73)

Abbreviations: HR, hazard ratios; CI, confidence intervals; *Propensity score analysis, inverse probability weighting, including hospital clustering as random effect covariate; multiple imputed analysis.

[^]Lopinavir/ritonavir or darunavir/cobicistat or tocilizumab or sarilumab or remdesivir or corticosteroids.

^{**}Missing data for N=178. Frequencies and hazard ratios are based on a case complete analysis (N=3,273) without missing data for C-reactive Protein; multiple imputed analysis (N=3,451) yielded very similar results.

301 ment (78.4%), in comparison with non-HCQ patients (46.3%). Anyway,
302 our findings are adjusted for concomitant other drugs use.

303 While the US studies were confined to one hospital only or a defined
304 relatively small area in the Country, our study included 33 hospitals
305 distributed all over Italy, covering regions with a high number of cases
306 and a high intra-hospital mortality and regions with a lower burden
307 of the disease. The participating Italian clinical centers have different
308 healthcare facilities, different size, specialization, and ownership, and
309 therefore quite closely represent the real-life Italian approach to COVID-
310 19. Moreover, they differed for the percentage of use of HCQ and for
311 the rate of in-hospital mortality that ranged between 34.1 and 1.5 per
312 1,000 persons/day. To consider this variability, we adjusted the analy-
313 sis for recruiting center and performed a number of subgroup analyses.
314 In all circumstances, the association between HCQ use and a reduced
315 risk of death of about 30% was maintained. Quite interestingly, the in-

316 verse association of HCQ with inpatient mortality was more evident in
317 elderly, in patients who experienced a higher degree of COVID-19 sever-
318 ity or especially having elevated C-reactive protein, suggesting that the
319 anti-inflammatory potential of HCQ may have had more important role
320 rather than its antiviral properties. HCQ, indeed, beside an antiviral ac-
321 tivity, may have both anti-inflammatory and anti-thrombotic effects [8].
322 This can justify its effect in reducing mortality risk, since Sars-Cov-2 can
323 induce pulmonary microthrombi and coagulopathy, that are a possible
324 cause of its severity [37,38] and the lack in preventing SARS-CoV-2 in-
325 fection after exposure [26]

326 Nevertheless, large randomized clinical trials on the efficacy of HCQ
327 on hard end-points are still lacking and the largest observational study
328 showing no effect in reducing mortality has been retracted [16,17],
329 Agencies have suspended clinical trials on the efficacy of HCQ on
330 COVID-19 disease or have restricted its use only to patients included
331

331 in clinical trials, in the absence of an ample, serene and balanced dis-
332 cussion at international level.

333 Very recently, a large RCT has become available as a pre-print pub-
334 lication [39], reporting no beneficial effect of HCQ in patients hospital-
335 ized with COVID-19. However, the dose of HCQ used in that trial was
336 almost the double of that administered in our real life conditions. A re-
337 duced mortality was also observed by other observational studies using
338 low or intermediate doses of HCQ [40,41].

339 Moreover, in our study patients taking HCQ more frequently re-
340 ceived other anti-COVID drugs, whose interaction in reducing mortality
341 cannot be completely ruled-out. Of note, despite the higher dosage used,
342 the RCT did not show any excess in ventricular tachycardia or ventric-
343 ular fibrillation in the HCQ arm (39).

344 Therefore, it will be very important to compare results of studies
345 with different mode of use and doses of HCQ, different characteristics
346 of treated and untreated patients and different academic or real-world
347 conditions.

348 4.1. Strengths and limitations

349 A major strength of this study is the large, unselected patient sample
350 from 33 hospitals, covering the entire Italian territory. Patient sampling
351 covered all the overt epidemic period in Italy. Several statistical ap-
352 proaches were used to overcome biases due to the observational nature
353 of the investigation.

354 This study has however, several recognized limitations. The study
355 population pertains to Italy, and the results obtained may not be appli-
356 cable to other populations with a possibly different geographical and
357 socio-economic conditions and natural history of COVID-19. Due to the
358 retrospective nature of the study, some parameters were not available
359 in all patients, and all in-hospital medications might have been not fully
360 recorded. Moreover, although guidelines on the use of HCQ in COVID-
361 19 patients had been published in Italy since the first phase of the pan-
362 demic, individual centers could have deviated from recommendations
363 and used different doses or treatment schemes. We have no information
364 on the HCQ doses used individually nor of their possible association with
365 azithromycin. Moreover, adverse events possibly related to drug therapy
366 were not collected, thus we cannot exclude bias due to therapy inter-
367 ruption because of side effects; we do not know whether some deaths
368 could have been due to cardiovascular complications of HCQ. However,
369 recent data on Italian wards showed that COVID-19 patients receiving
370 HCQ and azithromycin had a QTc-interval longer than before therapy,
371 but did not experience, during their hospital stay, any arrhythmic com-
372 plications, such as syncope or life-threatening ventricular arrhythmias
373 [42], a finding also reported by the RCT mentioned above (39).

374 Finally, the possibility of unmeasured residual confounding cannot
375 be completely ruled-out. However, the E-value for the lower boundary
376 of the confidence interval of our main result is 1.67, indicating that the
377 confidence interval could be moved to include the null by a strong un-
378 measured confounder associated with both HCQ treatment and death
379 with a risk ratio of 1.67-fold for each, above and beyond all the mea-
380 sured confounders. Weaker confounders, however, could not do so.

381 5. Conclusions

382 Our study, including a large real life sample of patients hospitalized
383 with COVID-19 all over Italy, shows that HCQ use (200 mg twice/day)
384 was associated with a 30% reduction of overall in-hospital mortality.
385 In the absence of clear-cut results from controlled, randomized clinical
386 trials, our data do not discourage the use of HCQ in inpatients with
387 COVID-19. Given the observational design of our study, however, these
388 results should be transferred with caution to clinical practice.

389 Source of funding

390 None.

Declaration of Competing Interests

None.

CRediT authorship contribution statement

Augusto Di Castelnuovo: Conceptualization, Data curation, Invest- 394
igation, Supervision, Writing - review & editing, Writing - original 395
draft. **Simona Costanzo:** Investigation, Supervision, Writing - review 396
& editing. **Andrea Antinori:** Investigation, Supervision, Writing - re- 397
view & editing. **Nausicaa Berselli:** Investigation, Supervision, Writing 398
- review & editing. **Lorenzo Blandi:** Investigation, Supervision, Writing 399
- review & editing. **Raffaele Bruno:** Investigation, Supervision, Writing 400
- review & editing. **Roberto Cauda:** Investigation, Supervision, Writ- 401
ing - review & editing. **Giovanni Guaraldi:** Investigation, Supervision, 402
Writing - review & editing. **Lorenzo Menicanti:** Investigation, Super- 403
vision, Writing - review & editing. **Iliaria My:** Investigation, Supervi- 404
sion, Writing - review & editing. **Giustino Parruti:** Investigation, Super- 405
vision, Writing - review & editing. **Giuseppe Patti:** Investigation, 406
Supervision, Writing - review & editing. **Stefano Perlini:** Investigation, 407
Supervision, Writing - review & editing. **Francesca Santilli:** Investi- 408
gation, Supervision, Writing - review & editing. **Carlo Signorelli:** In- 409
vestigation, Supervision, Writing - review & editing. **Enrico Spinoni:** 410
Investigation, Supervision, Writing - review & editing. **Giulio G. Ste- 411
fanini:** Investigation, Supervision, Writing - review & editing, Formal 412
analysis. **Alessandra Vergori:** Investigation, Supervision, Writing - re- 413
view & editing. **Walter Ageno:** Investigation, Supervision, Writing - 414
review & editing. **Antonella Agodi:** Investigation, Supervision, Writ- 415
ing - review & editing. **Luca Aiello:** Investigation, Supervision, Writ- 416
ing - review & editing. **Piergiuseppe Agostoni:** Investigation, Super- 417
vision, Writing - review & editing. **Samir Al Moghazi:** Investigation, 418
Supervision, Writing - review & editing. **Marinella Astuto:** Investiga- 419
tion, Supervision, Writing - review & editing. **Filippo Aucella:** Investi- 420
gation, Supervision, Writing - review & editing. **Greta Barbieri:** In- 421
vestigation, Supervision, Writing - review & editing. **Alessandro Barto- 422
lioni:** Investigation, Supervision, Writing - review & editing. **Mari- 423
alaura Bonaccio:** Investigation, Supervision, Writing - review & editing. 424
Paolo Bonfanti: Investigation, Supervision, Writing - review & editing. 425
Francesco Cacciatore: Investigation, Supervision, Writing - review & 426
editing. **Lucia Caiano:** Investigation, Supervision, Writing - review & 427
editing. **Francesco Cannata:** Investigation, Supervision, Writing - re- 428
view & editing. **Laura Carrozzi:** Investigation, Supervision, Writing - 429
review & editing. **Antonio Cascio:** Investigation, Supervision, Writing 430
- review & editing. **Arturo Ciccullo:** Investigation, Supervision, Writ- 431
ing - review & editing. **Antonella Cingolani:** Investigation, Supervision, 432
Writing - review & editing. **Francesco Cipollone:** Investigation, Super- 433
vision, Writing - review & editing. **Claudia Colomba:** Investigation, Su- 434
pervision, Writing - review & editing. **Francesca Crosta:** Investigation, 435
Supervision, Writing - review & editing. **Chiara Dal Pra:** Investigation, 436
Supervision, Writing - review & editing. **Gian Battista Danzi:** Invest- 437
igation, Supervision, Writing - review & editing. **Damiano D'Ardes:** 438
Investigation, Supervision, Writing - review & editing. **Katleen de Gae- 439
tano Donati:** Investigation, Supervision, Writing - review & editing, 440
Writing - original draft. **Paola Del Giacomo:** Investigation, Supervi- 441
sion, Writing - review & editing. **Francesco Di Gennaro:** Investigation, 442
Supervision, Writing - review & editing. **Giuseppe Di Tano:** Investi- 443
gation, Supervision, Writing - review & editing. **Giampiero D'Offizi:** 444
Investigation, Supervision, Writing - review & editing. **Tommaso Filip- 445
pini:** Investigation, Supervision, Writing - review & editing. **Francesco 446
Maria Fusco:** Investigation, Supervision, Writing - review & editing. 447
Ivan Gentile: Investigation, Supervision, Writing - review & editing. 448
Alessandro Gialluisi: Investigation, Supervision, Writing - review & 449
editing. **Giancarlo Gini:** Investigation, Supervision, Writing - review & 450
editing. **Elvira Grandone:** Investigation, Supervision, Writing - review 451
& editing. **Leonardo Grisafi:** Investigation, Supervision, Writing - 452
review & editing. **Gabriella Guarnieri:** Investigation, Supervision, 453

454 **Writing - review & editing.** Silvia Lamonica: Investigation, Super-
 455 **vision, Writing - review & editing.** Francesco Landi: Investigation,
 456 **Supervision, Writing - review & editing.** Armando Leone: Investi-
 457 **gation, Supervision, Writing - review & editing.** Gloria Maccagni:
 458 **Investigation, Supervision, Writing - review & editing.** Sandro Mac-
 459 **carella: Investigation, Supervision, Writing - review & editing.** An-
 460 **drea Madaro: Investigation, Supervision, Writing - review & edit-**
 461 **ing.** Massimo Mapelli: Investigation, Supervision, Writing - review
 462 **& editing.** Riccardo Maragna: Investigation, Supervision, Writing -
 463 **review & editing.** Lorenzo Marra: Investigation, Supervision, Writ-
 464 **ing - review & editing.** Giulio Maresca: Investigation, Supervision,
 465 **Writing - review & editing.** Claudia Marotta: Investigation, Super-
 466 **vision, Writing - review & editing.** Franco Mastroianni: Investiga-
 467 **tion, Supervision, Writing - review & editing.** Methodology. Maria
 468 **Mazzitelli: Investigation, Supervision, Writing - review & editing.**
 469 **Alessandro Mengozzi: Investigation, Supervision, Writing - review**
 470 **& editing.** Francesco Menichetti: Investigation, Supervision, Writ-
 471 **ing - review & editing.** Marianna Meschiari: Investigation, Super-
 472 **vision, Writing - review & editing.** Filippo Minutolo: Investigation,
 473 **Supervision, Writing - review & editing.** Arturo Montineri: Investi-
 474 **gation, Supervision, Writing - review & editing.** Roberta Mussinelli:
 475 **Investigation, Supervision, Writing - review & editing.** Cristina
 476 **Mussini: Investigation, Supervision, Writing - review & editing.**
 477 **Maria Musso: Investigation, Supervision, Writing - review & edit-**
 478 **ing.** Anna Odone: Investigation, Supervision, Writing - review &
 479 **editing.** Marco Olivieri: Investigation, Supervision, Writing - review &
 480 **editing.** Software. Emanuela Pasi: Investigation, Supervision, Writing
 481 **- review & editing.** Francesco Petri: Investigation, Supervision, Writ-
 482 **ing - review & editing.** Biagio Pinchera: Investigation, Supervision,
 483 **Writing - review & editing.** Carlo A. Pivato: Investigation, Supervision,
 484 **Writing - review & editing.** Venerino Poletti: Investigation, Super-
 485 **vision, Writing - review & editing.** Claudia Ravaglia: Investigation, Su-
 486 **pervision, Writing - review & editing.** Massimo Rinaldi: Investigation,
 487 **Supervision, Writing - review & editing.** Andrea Rognoni: Investiga-
 488 **tion, Supervision, Writing - review & editing.** Marco Rossato: Investi-
 489 **gation, Supervision, Writing - review & editing.** Iliaria Rossi: Investiga-
 490 **tion, Supervision, Writing - review & editing.** Marianna Rossi: Investi-
 491 **gation, Supervision, Writing - review & editing.** Anna Sabena: Investi-
 492 **gation, Supervision, Writing - review & editing.** Francesco Salinaro:
 493 **Investigation, Supervision, Writing - review & editing.** Vincenzo San-
 494 **giovanni: Investigation, Supervision, Writing - review & editing.** Carlo
 495 **Sanrocco: Investigation, Supervision, Writing - review & editing.** Laura
 496 **Scorzolini: Investigation, Supervision, Writing - review & editing.** Raf-
 497 **faella Sgariglia: Investigation, Supervision, Writing - review & editing.**
 498 **Paola Giustina Simeone: Investigation, Supervision, Writing - review &**
 499 **editing.** Michele Spinicci: Investigation, Supervision, Writing - review
 500 **& editing.** Enrico Maria Trecarichi: Investigation, Supervision, Writing
 501 **- review & editing.** Amedeo Venezia: Investigation, Supervision, Writ-
 502 **ing - review & editing.** Giovanni Veronesi: Investigation, Supervision,
 503 **Writing - review & editing.** Formal analysis. Roberto Vettor: Investi-
 504 **gation, Supervision, Writing - review & editing.** Andrea Vianello: Investi-
 505 **gation, Supervision, Writing - review & editing.** Marco Vinceti: Investi-
 506 **gation, Supervision, Writing - review & editing.** Laura Vocciante: Investi-
 507 **gation, Supervision, Writing - review & editing.** Raffaele De Caterina:
 508 **Conceptualization, Investigation, Supervision, Writing - review & edit-**
 509 **ing, Writing - original draft.** Licia Iacoviello: Conceptualization, Data
 510 **curation, Investigation, Investigation, Supervision, Writing - review &**
 511 **editing, Writing - original draft.**

512 Acknowledgments

513 We thank the participating clinical centres included in this cohort.
 514 This Article is dedicated to all the patients who suffered or died, often
 515 in solitude, due to COVID-19; their tragic fate gave us moral strength to
 516 initiate and complete this research.

The Authors alone are responsible for the views expressed in this Ar-
 517 ticle. They do not necessarily represent the views, decisions, or policies
 518 of the Institutions with which they are affiliated.
 519

Appendix 1

Augusto Di Castelnuovo^a, Simona Costanzo^b, Andrea Antinori^c,
 Nausicaa Berselli^d, Lorenzo Blandi^e, Raffaele Bruno^{f,g}, Roberto
 Cauda^{h,i}, Giovanni Guaraldi^j, Lorenzo Menicanti^e, Iliaria My^k, Giustino
 Parruti^l, Giuseppe Patti^m, Stefano Perlini^{n,o}, Francesca Santilli^p,
 Carlo Signorelli^q, Enrico Spinoni^m, Giulio G. Stefanini^k, Alessandra
 Vergori^r, Walter Ageno^s, Antonella Agodi^t, Luca Aiello^u, Piergiuseppe
 Agostoni^{v,w}, Samir Al Moghazi^x, Marinella Astuto^t, Filippo Aucella^y,
 Greta Barbieri^z, Alessandro Bartoloni^{aa}, Marialaura Bonaccio^b, Paolo
 Bonfanti^{ab,ac}, Francesco Cacciatore^{ad}, Lucia Caiano^e, Francesco
 Cannata^k, Laura Carrozzi^{ae}, Antonio Cascio^{af}, Arturo Ciccullo^h,
 Antonella Cingolani^{hi}, Francesco Cipollone^p, Claudia Colomba^{af},
 Francesca Crosta^l, Chiara Dal Pra^{ag}, Gian Battista Danzi^{ah}, Dami-
 ano D'Ardes^p, Kathleen de Gaetano Donati^h, Paola Del Giacomo^b,
 Francesco Di Gennaro^{ai}, Giuseppe Di Tano^{ah}, Giampiero D'Offizi^{aj},
 Tommaso Filippini^d, Francesco Maria Fusco^{ak}, Ivan Gentile^{al}, Alessan-
 dro Gialluisi^b, Giancarlo Gini^s, Elvira Grandone^y, Leonardo Grisafi^m,
 Gabriella Guarnieri^{am}, Silvia Lamonica^h, Francesco Landi^u, Armando
 Leone^{an}, Gloria Maccagni^{ah}, Sandro Maccarella^{ao}, Andrea Madaro^{ap},
 Massimo Mapelli^{v,w}, Riccardo Maragna^{v,w}, Lorenzo Marra^{an}, Giulio
 Maresca^{aq}, Claudia Marotta^{ai}, Franco Mastroianni^{ap}, Maria Mazzitelli^{ar},
 Alessandro Mengozzi^z, Francesco Menichetti^z, Marianna Meschiari^j,
 Filippo Minutolo^{as}, Arturo Montineri^{at}, Roberta Mussinelli^q, Cristina
 Mussini^j, Maria Musso^{au}, Anna Odone^q, Marco Olivieri^{av}, Emanuela
 Pasi^{aw}, Francesco Petri^{ab}, Biagio Pinchera^{al}, Carlo A. Pivato^k, Venerino
 Poletti^{ax}, Claudia Ravaglia^{ax}, Massimo Rinaldi^{ap}, Andrea Rognoniⁿ,
 Marco Rossato^{ag}, Iliaria Rossi^p, Marianna Rossi^{ab}, Anna Sabenaⁿ,
 Francesco Salinaroⁿ, Vincenzo Sangiovanni^{ak}, Carlo Sanrocco^l, Laura
 Scorzolini^{ay}, Raffaella Sgariglia^{aq}, Paola Giustina Simeone^l, Michele
 Spinicci^{aa}, Enrico Maria Trecarichi^{ar}, Amedeo Venezia^{ap}, Giovanni
 Veronesi^s, Roberto Vettor^{ag}, Andrea Vianello^{am}, Marco Vinceti^{d,az},
 Laura Vocciante^{aq}, Raffaele De Caterina^{ai}, Licia Iacoviello^{b,s}

^aMediterranea Cardiocentro, Napoli. Italy ^bDepartment of Epidemi-
 ology and Prevention, IRCCS Neuromed, Pozzilli (IS). Italy ^cUOC Im-
 munodeficienze Virali, National Institute for Infectious Diseases "L.
 Spallanzani", IRCCS. Roma. Italy ^dSection of Public Health, Department
 of Biomedical, Metabolic and Neural Sciences, University of Modena
 and Reggio Emilia, Modena. Italy ^eIRCCS Policlinico San Donato, San
 Donato Milanese. Italy ^fDivision of Infectious Diseases I, Fondazione IR-
 CCS Policlinico San Matteo, Pavia. Italy ^gDepartment of Clinical, Sur-
 gical, Diagnostic, and Paediatric Sciences, University of Pavia, Pavia.
 Italy ^hFondazione Policlinico Universitario A. Gemelli IRCCS, Roma.
 Italy ⁱUniversità Cattolica del Sacro Cuore- Dipartimento di Sicurezza
 e Bioetica Sede di Roma, Roma. Italy ^jInfectious Disease Unit, Depart-
 ment of Surgical, Medical, Dental and Morphological Sciences, Univer-
 sity of Modena and Reggio Emilia, Modena. Italy ^kHumanitas Clinical
 and Research Hospital IRCCS, Rozzano-Milano. Italy ^lDepartment of In-
 fectious Disease, Azienda Sanitaria Locale (AUSL) di Pescara, Pescara.
 Italy ^mUniversity of Eastern Piedmont, Maggiore della Carità Hospi-
 tal, Novara. Italy ⁿEmergency Department, IRCCS Policlinico San Mat-
 teo Foundation, Pavia. Italy ^oDepartment of Internal Medicine, Univer-
 sity of Pavia, Pavia. Italy ^pDepartment of Medicine and Aging, Clinica
 Medica, "SS. Annunziata" Hospital and University of Chieti, Chieti.
 Italy ^qSchool of Medicine, Vita-Salute San Raffaele University, Milano.
 Italy ^rHIV/AIDS Department, National Institute for Infectious Diseases
 "Lazzaro Spallanzani"-IRCCS, Roma. Italy ^sDepartment of Medicine and
 Surgery, University of Insubria, Varese. Italy ^tDepartment of Medi-
 cal and Surgical Sciences and Advanced Technologies "G.F. Ingrasia",
 University of Catania; AOU Policlinico-Vittorio Emanuele, Catania.
 Italy ^uUOC. Anestesia e Rianimazione. Dipartimento di Chirurgia
 Generale Ospedale Morgagni-Pierantoni, Forlì. Italy ^vCentro Car-

diologico Monzino IRCCS, Milano. Italy ^wDepartment of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, Milano. Italy ^xInfezioni Sistemiche dell'Immunodepresso, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Roma. Italy ^yFondazione I.R.C.C.S. "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia. Italy ^zDepartment of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Pisana, and University of Pisa, Pisa. Italy ^{aa}Department of Experimental and Clinical Medicine. University of Florence, Firenze. Italy ^{ab}UOC Malattie Infettive, Ospedale San Gerardo, ASST Monza, Monza. Italy ^{ac}School of Medicine and Surgery, University of Milano-Bicocca, Milano. Italy ^{ad}Department of Translational Medical Sciences. University of Naples, Federico II, Napoli. Italy ^{ae}Cardiovascular and Thoracic Department, Azienda Ospedaliero-Universitaria Pisana, and University of Pisa, Pisa. Italy ^{af}Infectious and Tropical Diseases Unit- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) - University of Palermo, Palermo. Italy ^{ag}Clinica Medica 3, Department of Medicine - DIMED, University hospital of Padova, Padova. Italy ^{ah}Department of Cardiology, Ospedale di Cremona, Cremona. Italy ^{ai}Medical Direction, IRCCS Neuromed, Pozzilli (IS). Italy ^{aj}UOC Malattie Infettive-Epatologia, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Roma. Italy ^{ak}UOC Infezioni Sistemiche e dell'Immunodepresso, Azienda Ospedaliera dei Colli, Ospedale Cotugno. Napoli. Italy ^{al}Department of Clinical Medicine and Surgery. University of Naples "Federico II", Napoli. Italy ^{am}Respiratory Pathophysiology Division, Department of Cardiology, Thoracic and Vascular Sciences, University of Padova, Padova. Italy ^{an}UOC di Pneumologia, P.O. San Giuseppe Moscati, Taranto. Italy ^{ao}ASST Milano Nord - Ospedale Edoardo Bassini, Cinisello Balsamo. Italy ^{ap}COVID-19 Unit. EE Ospedale Regionale F. Miulli, Acquaviva delle Fonti (BA). Italy ^{aq}UOC Medicina - PO S. Maria di Loreto Nuovo -ASL Napoli 1 Centro. Napoli ^{ar}Infectious and Tropical Diseases Unit. Department of Medical and Surgical Sciences "Magna Graecia" University, Catanzaro. Italy ^{as}Dipartimento di Farmacia, Università di Pisa, Pisa, Italy. ^{at}U.O. C. Malattie Infettive e Tropicali, P.O. "San Marco", AOU Policlinico-Vittorio Emanuele, Catania. Italy ^{au}UOC Malattie Infettive-Apparato Respiratorio, National Institute for Infectious Diseases "L. Spallanzani", IRCCS, Roma. Italy ^{av}Computer Service, University of Molise, Campobasso. Italy. ^{aw}Medicina Interna. Ospedale di Ravenna. AUSL della Romagna, Ravenna. Italy ^{ax}UOC Pneumologia. Dipartimento di Malattie Apparato Respiratorio e Torace. Ospedale Morgagni- Pierantoni Forlì, Forlì. Italy ^{ay}UOC Malattie Infettive ad Alta Intensità di Cura, National Institute for Infectious Diseases "L. Spallanzani", IRCCS, Roma. Italy ^{az}Department of Epidemiology, Boston University School of Public Health, Boston. USA.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.ejim.2020.08.019](https://doi.org/10.1016/j.ejim.2020.08.019).

References

- [1] Shukla AM, Wagle Shukla A. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. *Drugs Context* 2019;8:2019 9-1. Published 2019 Nov 25. doi:10.7573/dic.2019-9-1.
- [2] Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect Dis* 2003;3(11):722–7. doi:10.1016/s1473-3099(03)00806-5.
- [3] Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. *J Gen Virol* 2015;96(12):3484–92. doi:10.1099/jgv.0.000309.
- [4] Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. *Cell Biochem Funct* 2016;34(4):191–6. doi:10.1002/cbf.3182.
- [5] Savarino A, Shayt J. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. *Retrovirology* 2015;12:51. Published 2015 Jun 18. doi:10.1186/s12977-015-0178-0.
- [6] de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory

- syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother* 2014;58(8):4875–84. doi:10.1128/AAC.03011-14.
- [7] Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents* 2020, Mar 12. doi:10.1016/j.ijantimicag.2020.105938.
- [8] Quiros Roldan E, Biasiotto G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): a role for iron homeostasis? [published online ahead of print, 2020 May 13]. *Pharmacol Res*. 2020;158:104904. doi:10.1016/j.phrs.2020.104904.
- [9] Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology*. 2005;2:69. Published 2005 Aug 22. doi:10.1186/1743-422X-2-69.
- [10] Mercurio NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). *JAMA Cardiol* 2020 May 1. doi:10.1001/jamacardio.2020.1834.
- [11] Saleh M, Gabriels J, Chang D, et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 Infection. *Circ Arrhythm Electrophysiol*. 2020 Apr 29. doi:10.1161/CIRCEP.120.008662.
- [12] Food and Drug Administration (FDA) Fact sheet for health care providers: emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. Posted April 2020;27. Available at: <https://www.fda.gov/media/136537/download> (Accessed May 31, 2020).
- [13] European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. Available at: <https://www.ema.europa.eu/en/news/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes>. (Accessed June, 26, 2020).
- [14] Agenzia Italiana del Farmaco (AIFA). Idrossiclorochina nella terapia dei pazienti adulti con COVID-19. Available at: https://www.aifa.gov.it/documents/20142/1123276/idrossiclorochina_29.04.2020.pdf/386d6ea3-c79b-6437-f457-23d33df74256. (Accessed June, 26, 2020).
- [15] Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory Syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020 Mar 9. doi:10.1093/cid/ciaa237.
- [16] Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *Lancet* 2020. published online May 22. doi:10.1016/S0140-6736(20)31180-6.
- [17] Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [retraction of: *Lancet*. 2020 May 22;]. *Lancet* 2020;395(10240):1820. doi:10.1016/S0140-6736(20)31324-6.
- [18] World Health Organization. Hydroxychloroquine and COVID-19. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> (Accessed June, 26, 2020).
- [19] Agenzia Italiana del Farmaco (AIFA). AIFA sospende l'autorizzazione all'utilizzo di idrossiclorochina per il trattamento del COVID-19 al di fuori degli studi clinici. Available at: <https://www.aifa.gov.it/-/aifa-sospende-l-autorizzazione-all-utilizzo-di-idrossiclorochina-per-il-trattamento-del-covid-19-al-di-fuori-degli-studi-clinici>. (Accessed May 31, 2020).
- [20] Chowdhury MS, Rathod J, Gernsheimer J. A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. *Acad Emerg Med* 2020 May 2. doi:10.1111/acem.14005.
- [21] Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einaiv S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care* 2020;57:279–83. doi:10.1016/j.jcrc.2020.03.005.
- [22] Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). *Int J Rheum Dis* 2020;23(5):613–19. doi:10.1111/1756-185X.13842.
- [23] Das S, Bhowmick S, Tiwari S, Sen S. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19) [published online ahead of print, 2020 May 28]. *Clin Drug Investig*. 2020 10.1007/s40261-020-00927-1. doi:10.1007/s40261-020-00927-1.
- [24] Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review [published online ahead of print, 2020 May 27]. *Ann Intern Med*. 2020 10.7326/M20-2496. doi:10.7326/M20-2496.
- [25] Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* 2020 May 14;369:m1849. doi:10.1136/bmj.m1849.
- [26] Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19 [published online ahead of print, 2020 Jun 3]. *N Engl J Med*. 2020 NEJMoa2016638. doi:10.1056/NEJMoa2016638.
- [27] Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. *N Engl J Med* 2020;382(25):2411–18. doi:10.1056/NEJMoa2012410.
- [28] Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State [published online ahead of print, 2020 May 11]. *JAMA*. 2020;323(24):2493–502. doi:10.1001/jama.2020.8630.
- [29] COVID-19 Coronavirus pandemic worldometers. [https://www.worldometers.info/coronavirus/#countries] (Accessed June, 26, 2020).

- 733 [30] Di Castelnuovo A, De Caterina R, de Gaetano G, Iacoviello L. Controversial relationship between renin-angiotensin system inhibitors and severity of COVID-19: announcing a large multicentre case-control study in Italy [published online ahead of print, 2020 May 8]. *Hypertension*. 2020. doi:10.1161/HYPERTENSION-AHA.120.1537010.1161/HYPERTENSIONAHA.120.15370.
- 734
- 735
- 736
- 737 [31] Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. Available at: <https://apps.who.int/iris/bitstream/handle/10665/330893/WHO-nCoV-Clinical-2020.3-eng.pdf?sequence=1&isAllowed=y> (Accessed June, 26, 2020).
- 738
- 739
- 740 [32] Rubin DB. *Multiple imputation for nonresponse in surveys*. New York: John Wiley; 1987.
- 741
- 742
- 743 [33] Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. *Stat Med* 2004;23(3):369–88. doi:10.1002/sim.1599.
- 744
- 745 [34] Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. *Health Serv Res* 2014;49(5):1701–20. doi:10.1111/1475-6773.12182.
- 746
- 747 [35] VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. *Ann Intern Med* 2017;167(4):268–74. doi:10.7326/M16-2607.
- 748
- 749 [36] Società Italiana di Malattie Infettive e Tropicali (SIMIT). *Vademecum per la cura delle persone con malattia da COVID-19*. Available at: <http://www.simit.org/medias/1569-covid19-vademecum-13-03-202.pdf>, (Accessed June 26, 2020).
- 750
- 751
- 752
- 753
- 754
- 755 [37] McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in covid-19 induced pneumonia and macrophage activation syndrome-like disease. *Autoimmun Rev* 2020;19(6):102537. doi:10.1016/j.autrev.2020.102537.
- 756
- 757
- 758
- 759 [38] Thachil J. The versatile heparin in COVID-19. *J Thromb Haemost* 2020;18(5):1020–2. doi:10.1111/jth.14821.
- 760
- 761 [39] Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: preliminary results from a multicentre, randomized, controlled trial. *medRxiv* 2020;07:15. 20151852 <https://doi.org/10.1101/2020.07.15.201518522020>.
- 762
- 763
- 764 [40] Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis* 2020;97:396–403. doi:10.1016/j.ijid.2020.06.099.
- 765
- 766
- 767 [41] Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis [published online ahead of print, 2020 Jun 25]. *Travel Med Infect Dis*. 2020;36:101791. doi:10.1016/j.tmaid.2020.101791.
- 768
- 769
- 770 [42] Cipriani A, Zorzi A, Ceccato D, et al. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin [published online ahead of print, 2020 May 19]. *Int J Cardiol*. 2020;S0167-5273(20)32223-3. doi:10.1016/j.ijcard.2020.05.036.
- 771
- 772
- 773
- 774
- 775